Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 25 siguiente >>
Presentar resultados
Seleccionar todas
1.
Greenhalgh T, Maskrey N. Evidence based medicine a movement in crisis?. BMJ 2014;348:g3725. [Ref.ID 98053]
2.Enlace a cita original
Moynihan R, Henry D, Moons KGM. Using evidence to combat overdiagnosis and overtrea tests, and disease definitions in the time of too much. PLOS Medicine 2014;11:e1001655. [Ref.ID 97789]
3.Enlace a cita original Cita con resumen
Moynihan R. What is disease? And why it's a healthy question. BMJ 2013;346:26. [Ref.ID 94762]
4.Tiene citas relacionadas
Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. N Engl J Med 2012;366:2223-4. [Ref.ID 93175]
5.Tiene citas relacionadas Cita con resumen
Gier MT, Skripoconoka V, Sánchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh W-J, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60. [Ref.ID 93171]
6. Cita con resumen
Anónimo. So, what exactly is a cytokine?. Drug Ther Bull 2009;47:89-91. [Ref.ID 86611]
7. Cita con resumen
Anónimo. Understanding statistical terms: 1. Drug Ther Bull 2009;47:22-4. [Ref.ID 85346]
8.
Dear JW, Lilitkarntakul P, Webb DJ. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol 2006;62:264-71. [Ref.ID 77914]
9.
Anónimo. Unfinished business: clinical pharmacology and world health. WHO Drug Information 2005;19:201. [Ref.ID 75400]
10.
Langa KM, Foster NL, Larson EB. Mixed dementia. Emerging concepts and therapeutic implications. JAMA 2004;292:2901-8. [Ref.ID 72098]
11.
Aronson JK. ON the waterfront - the breadth and depth of clinical pharmacology. Br J Clin Pharmacol 2004;57:693-4. [Ref.ID 70373]
12.
Macedo A, Farré M, Baños JE. Placebo effect and placebos: what are we taking about? Some conceptual and historical considerations. Eur J Clin Pharmacol 2003;59:337-42. [Ref.ID 67152]
13. Cita con resumen
Rawlins M D. Clinical pharmacology and therapeutics into the future. Br J Clin Pharmacol 2003;55:483-5. [Ref.ID 66821]
14.
Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003;138:644-50. [Ref.ID 65731]
15.
Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther 2003;73:279-83. [Ref.ID 65588]
16.
Levy M, Reidenberg M M. What has been the impact of the concept of essential drugs?. Clin Pharmacol Ther 2003;73:275-8. [Ref.ID 65587]
17.
Loewert M. Concept de la surface corporelle historique et pertinance dans l'adaptation poslogique. Bulletin d'Information du Médicament et de Pharmacovigilance CRIM Rennes 2003;105:1-4. [Ref.ID 65191]
18.Tiene citas relacionadas
Jenkinson ML. Prescribing errors. Lancet 2002;360:256. [Ref.ID 63155]
19.Tiene citas relacionadas
Tanna N, Pitkin J. Prescribing errors. Lancet 2002;360:255-6. [Ref.ID 63154]
20.Tiene citas relacionadas
Koh THH, Budge D, Collie L. Prescribing errors. Lancet 2002;360:255. [Ref.ID 63153]
Seleccionar todas
 
 1 a 20 de 25 siguiente >>